Crucially, for patients with melanoma undergoing treatment with both a BRAF inhibitor (BRAFi) and a MEK inhibitor (MEKi), the respective NGFRhigh and MITFhigh transcriptional states in the tumor coexist at the initial drug-response phase, although there is clear interpatient variability regarding the predominant states [42]. The gene discussed is BRAF; the disease is melanoma.